KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$81.62M

FY 2026 · Annual

Investing Cash Flow

$18.68M

FY 2026 · Annual

-79.5% YoY

Financing Cash Flow

$162.64M

FY 2026 · Annual

+1.8% YoY

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Depreciation & Amortization743K718K816K941K1.45M
Deferred Income Tax00000
Stock-Based Compensation09.92M21.92M12.29M0
Change in Working Capital(12.32M)7.41M15.17M15.04M954K
Accounts Receivables(5.2M)(2.32M)8.18M(3.62M)(7.4M)
Inventory0000(3.43M)
Accounts Payables1.69M1.11M4.32M(4.97M)4.19M
Other Working Capital(8.81M)8.62M2.67M23.63M7.59M
Other Non-Cash Items15.78M(407K)(485K)2.27M80.26M
Operating Cash Flow(78.13M)(75.26M)(89.23M)(152.91M)(81.62M)
Capital Expenditures(931K)(1.2M)(443K)(434K)(1.71M)
Acquisitions (Net)00000
Purchases of Investments(136.92M)(98.25M)(189.23M)(30.57M)(84.78M)
Sales of Investments195.71M140.86M104.96M122.52M105.36M
Other Investing Activities00(401K)00
Investing Cash Flow57.86M41.42M(84.72M)91.02M18.68M
Debt Repayment00098.04M160.72M
Common Stock Issued1.58M56.58M96.95M61.69M1.92M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.53M53.77M00
Financing Cash Flow1.58M58.12M150.71M159.73M162.64M
Effect of Forex Changes(1.17M)1.24M(1.21M)1.98M(1.98M)
Net Change in Cash(19.86M)25.51M(24.45M)99.83M97.73M
Free Cash Flow(79.07M)(76.46M)(89.67M)(153.34M)(83.33M)

Free Cash Flow

Net Income to FCF bridge

FY2026

= Net Income-$164.3M
+ D&A$1.5M
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$954.0K
+ Other Non-Cash$80.3M
= Operating Cash Flow-$81.6M
- Capex-$1.7M
= Free Cash Flow-$83.3M

Analysis

FY2026 free cash flow is -$83.3M. FCF conversion is 50.7% of net income. Operating cash flow was -$81.6M, with capex of -$1.7M. The largest bridge item is Other Non-Cash at $80.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026

Does KALV generate free cash flow?

KalVista Pharmaceuticals, Inc. (KALV) generated -$83.33M of free cash flow in fiscal 2026.

How much operating cash flow does KALV produce?

Operating cash flow was -$81.62M, before capital expenditures of $1.71M.